Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Omid Farokhzad
Columbia University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tarveda Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Please see attached.
Please note that the subject of this FCOI Report -- Tarveda Therapeutics -- is the new name of the company previously reported in FCOI Report #10852. Apart from the change to the company's name, the details of the FCOI and the management have not changed.
Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of Biologics
Heart disease is the leading cause of morbidity and mortality in developed nations with an enormous societal and economic burden, and dangerous atherosclerosis plaques can develop due to a maladaptive chronic inflammatory response, which ultimately leads to blood clot formation and death in the form of heart attacks. In view of the fact that only certain types of atherosclerotic lesions reach this advanced stage of clinical relevance, the overall objective of this proposal is to understand the processes that influence the formation of these dangerous atherosclerotic lesions-and to do so in a manner that has tremendous therapeutic potential. In this context, we will study the mechanisms of a fundamental protective process that goes awry in atherosclerosis-called inflammation resolution-and we will try to enhance this protective process in an effective and safe manner by using tiny delivery systems, called nanoparticles, that deliver the resolution- promoting drugs directly to the atherosclerotic plaque in a controlled manner and can dampen this out of control inflammation process to a greater extent than the body's natural defenses can manage
Filed on November 17, 2016.
Tell us what you know about Omid Farokhzad's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Omid Farokhzad filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Selecta Biosciences | $100,000 - $149,999 |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Blend Therapeutics | $100,000 - $149,999 |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | BIND Biosciences | $80,000 - $99,999 |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | Selecta Biosciences | $80,000 - $99,999 |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | BIND Biosciences | Value cannot be readily determined |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | Selecta Biosciences | Value cannot be readily determined |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Tarveda Therapeutics | Value cannot be readily determined |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Selecta Biosciences | Value cannot be readily determined |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Blend Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.